NCT00413751已完成不适用
Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
研究概览
简要总结
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.
排除标准
- •Patients not meeting above stated age criteria
- •Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
- •History of serious ocular, neurological, cardiovascular disease
- •History of severe systemic disease
- •History of arrhythmias or high blood pressure
- •Patients currently taking any type of ocular or systemic medications except multivitamins.
- •Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular HypertensionOpen-Angle GlaucomaOcular HypertensionNCT00061529Alcon Research
已完成
2 期
Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric SubjectsOcular RednessNCT01675609Eye Therapies, LLC57
已完成
4 期
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT02003534Allergan376
已完成
4 期
The Effect of Lumify™ Eyedrops on Eyelid PositionEyelid DroopNCT03782701University of Miami43
已完成
3 期
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00652483Allergan433